Pending Claims

1. (original) An isothiazole derivative of the formula 1 or nontoxic salt thereof:

<Formula 1>



wherein, R_1 is hydrogen, alkoxy or halogen; and R_2 is methyl or amino group.

2. (original) The isothiazole derivative or nontoxic salt thereof according to Claim 1, wherein said isothiazole derivative is selected from a group consisting of:

4-(4-fluorophenyl)-3-(4-methanesulfonylphenyl)-5-methyl-isothiazol,

4-(5-methyl-3-phenyl-isothiazole-4-yl)-benzonesulfonamide,

4-[3-(4-bromophenyl)-5-methyl-isothiazlole-4-yl]-benzenesulfonamide,

4-[3-(4-methoxyphenyl)-5-methyl-isothiazole-4-yl]-benzenesulfonamide,

4-[3-(4-fluorophenyl)-5-methyl-isothiazole-4-yl]-benzenesulfonamide,

4-(4-methanesulfonylphenyl)-5-methyl-3-phenyl-isothiazole,

3-(4-bromophenyl)-4-(4-methanesulfonylphenyl)-5-methyl-isothiazole,

3-(4-methoxyphenyl)-4-(4-methanesulfonylphenyl)-5-methyl-isothiazole, and

3-(4-fluorophenyl)-4-(4-methanesulfonylphenyl)-5-methyl-isothiazole.

3.-5. (canceled)

6. (original) A pharmaceutical composition with antipyretic, analgesic and antiphlogistic activity, including a therapeutically effective amount of an isothiazole derivative or nontoxic salt thereof according to claim 1 or 2 as an effective component and a pharmaceutically acceptable carrier.